Picture of Mirati Therapeutics logo

MRTX Mirati Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapMomentum Trap

Momentum

Relative Strength (%)
1m-2.19%
3m-7.99%
6m+76.73%
1yr+12.29%
Volume Change (%)
10d/3m-30.32%
Price vs... (%)
52w High-8.71%
50d MA+2.01%
200d MA+29.61%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-77.08%
Return on Equity-69.95%
Operating Margin-2002.75%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Mirati Therapeutics EPS forecast chart

Profile Summary

Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
April 29th, 2013
Public Since
July 12th, 2013
No. of Shareholders
12
No. of Employees
587
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
70,147,706

MRTX Share Price Performance

Upcoming Events for MRTX

Q4 2023 Mirati Therapeutics Inc Earnings Release

Q1 2024 Mirati Therapeutics Inc Earnings Release

Mirati Therapeutics Inc Annual Shareholders Meeting

Similar to MRTX

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ